ADC Therapeutics pauses enrolment in mid-stage trial for cancer therapy
11/07/2023 12:17
July 11 (Reuters) - ADC Therapeutics ADCT.N said on Tuesday it had paused enrollment of new patients in a mid-stage study evaluating its drug Zynlonta along with rituximab for treating a type of blood cancer over safety concerns. (Reporting by Raghav Mahobe in Bengaluru; Editing by Sriraj Kalluvila) ((Raghav.Mahobe@thomsonreuters.com;))
Recent news on Adc Therapeutics
See all newsBrief: Adc Therapeutics Announces Comprehensive Strategic Financial Restructuring Marking Key Capital Structure Improvements
ADC Therapeutics SA reports results for the quarter ended June 30 - Earnings Summary
ADC Therapeutics Q2 loss narrows; cuts 17% workforce
ADC Therapeutics SA expected to post a loss of 21 cents a share - Earnings Preview
ADC Therapeutics SA expected to post a loss of 21 cents a share - Earnings Preview